Diabetic Nephropathy
📧 Sign up to get email alerts when something new happens for Diabetic Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Effects of Fenofibrate Therapy in Diabetic Nephropathy [Phase 3]
A Phase 3 clinical trial update examining the effects of fenofibrate therapy in diabetic nephropathy.
-
FDA approval · 2020-11-30FDA Approved: IRBESARTAN — Supplemental Application (AvKARE)
FDA approves AvKARE's supplemental application for IRBESARTAN, enabling continued marketing of the generic irbesartan product.
-
FDA approval · 2020-10-21FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Losartan Potassium by Aurobindo Pharma Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2020-07-24Clinical Trial Update: Bosentan Use in Patients With Diabetic Nephropathy [Phase 3]
A Phase 3 clinical trial investigating bosentan in patients with diabetic nephropathy has been terminated.
-
FDA label_change · 2020-05-19FDA Approved: CAPTOPRIL — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for captopril submitted by Solco Healthcare US, LLC, updating the labeling for the generic drug …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-05-11Clinical Trial Update: Nephropathy In Type 2 Diabetes and Cardio-renal Events [Phase 4]
Phase 4 trial update on nephropathy in type 2 diabetes with cardio-renal events; results completed and posted.
-
FDA approval · 2020-04-27FDA Approved: LISINOPRIL — Supplemental Application (Solco healthcare U.S., LLC)
FDA approved a supplemental application for lisinopril from Solco Healthcare U.S., LLC, approving a generic lisinopril product.
-
CLINICAL_TRIALS trial_result · 2020-04-21Clinical Trial Update: Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients [Phase 4]
Phase 4 trial assessing the effect of an SGLT2 inhibitor on proteinuria in patients with diabetic nephropathies.
-
CLINICAL_TRIALS trial_result · 2020-03-09Clinical Trial Update: Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy [Phase 4]
Phase 4 trial evaluating exenatide's effect on 24h urinary albumin excretion rate in patients with diabetic nephropathy.
-
FDA approval · 2020-03-03FDA Approved: CAPTOPRIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for CAPTOPRIL (captopril) from Hikma Pharmaceuticals USA Inc. under an ANDA. The action concerns…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Short Term Effects of a Hibiscus Sabdariffa and Stevia Rebaudiana Drink on Cardiac Relaxation and Urinary Albumin Excretion in a Group of Diabetic Type 2 Subjects [Phase 4]
Phase 4 clinical trial evaluating short-term effects of a Hibiscus sabdariffa and Stevia rebaudiana drink on cardiac relaxation and urinary …
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination [Phase 2]
Phase 2 clinical trial update assessing the efficacy of ACE inhibitors, MRAs, and a combination therapy in diabetic nephropathy with microal…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy [Phase 3]
Phase 3 trial evaluating the effects of canagliflozin on renal and cardiovascular outcomes in patients with type 2 diabetes and diabetic nep…
-
FDA approval · 2019-11-06FDA Approved: IRBESARTAN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for IRBESARTAN from Camber Pharmaceuticals, Inc., approving changes related to this product's use or…
-
FDA approval · 2019-11-06FDA Approved: VALSARTAN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for valsartan from Ascend Laboratories, updating the regulatory status of this generic antihypertens…
-
CLINICAL_TRIALS research · 2019-10-21Clinical Trial Update: Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes [Phase 4]
A Phase 4 clinical trial evaluating the effects of SGLT2 inhibition on albuminuria levels in patients with type 2 diabetes and diabetic neph…
-
FDA approval · 2019-08-20FDA Approved: VALSARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for VALSARTAN submitted by Unichem Pharmaceuticals (USA), Inc.
-
FDA approval · 2019-08-16FDA Approved: IRBESARTAN — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Irbesartan from Camber Pharmaceuticals, indicating an approved change to the existing ANDA a…
-
FDA approval · 2019-08-07FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approves a supplemental application for enalapril maleate by Taro Pharmaceuticals U.S.A., Inc., pertaining to an approved product (gener…
-
CLINICAL_TRIALS trial_result · 2019-07-24Clinical Trial Update: Use of Wharton Jelly in Diabetic Nephropathy [Phase 1, Phase 2]
Clinical trial update for use of Wharton jelly in diabetic nephropathy across Phase 1 and Phase 2.
-
FDA approval · 2019-07-05FDA Approved: LOSARTAN POTASSIUM TABLETS, 25 MG — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)
FDA approved Jubilant Cadista Pharmaceuticals' supplemental application for Losartan Potassium Tablets, 25 mg, under ANDA201170.
-
FDA approval · 2019-05-07FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Losartan Potassium from Unichem Pharmaceuticals (USA), Inc., authorizing the marketing of a gene…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Atrasentan Spermatogenesis and Testicular Function [Phase 2]
Phase 2 trial update on atrasentan focusing on effects on spermatogenesis and testicular function in nephropathy and diabetes patients; resu…
-
FDA approval · 2019-05-07FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Micro Labs Limited)
Supplemental application for Losartan Potassium from Micro Labs Limited has been approved by the FDA.
-
CLINICAL_TRIALS trial_result · 2019-04-24Clinical Trial Update: Study Of Diabetic Nephropathy With Atrasentan [Phase 3]
Phase 3 trial of atrasentan for diabetic nephropathy was terminated; results posted in 2019.